Leveraging the Science of Case Studies

Welcome, reader!

Did your organization just figure out how to solve a complex scientific problem? Have scientific strategies that can put you ahead of your competitors in the field and impress your clients? Case studies can be effective for putting out how you challenged an intricate problem, strategized its solution and had your team learn valuable lessons. Read on to know the different aspects of sharing your science through case studies and in turn leveraging them in furthering your work and business.

Leveraging the Science of Case Studies

Be it the data from a clinical trial, or a potent drug which showed promising results or simply a protocol with a better outcome, case studies can be influential tools to convey your message and story to clients and the larger audience. In this edition we highlight how Contract Research Organizations (CROs), Contract Development and Manufacturing Organizations (CDMOs) and the larger collection of healthtech and medtech companies can use case studies as an important medium for conveying their science and expertise.

Following are the different aspects of communicating science via case studies:

Highlight in-house capabilities: Case studies are a means to establish the company’s expertise and domain knowledge for providing cutting-edge solutions to problems. For instance, IQVIA showed through a case study how the IQVIA Patient Suite collaborated with a sponsor to pinpoint and eliminate adoption challenges, providing a seamless and powerful digital solution.

Gaining trust: Working towards building credibility and trust among consumers and clients is an important exercise and case studies can be pivotal tools for this. The diagnostic company bioMérieux showcased through a case study how the leading cosmetics brand Shiseido used one of their testing platforms to improve quality testing of products.

Solution-based approach: Describing the core problem and how the solution could perfectly fit into the scenario has to be the highlight of a case study. This Novotech case study examines the Phase I clinical trial of a COVID-19 drug and summarises how this difficult problem was tackled by their experienced team.

Building Domain Authority: Of the many documents that can establish industry authority, case studies can be important in showcasing the company’s uniqueness and leadership in the field. This case study shows how the partnership between Amgen and ZS successfully delivered an industry-leading big data solution.

Targeting new clients: Every company looking to put out a knowledge product has potential clients in mind. Case studies can highlight the strengths of the company, making clients choose them over competitors. In this instance, the company DelveInsight not only published the case study on benchmarking CDMOs, but also proceeded to publish it via PRNewswire, potentially attracting more clients.

Contributing to knowledge sharing: The company’s assets in the form of knowledge can be effectively disseminated to own teams and clients via case studies. This case study by Pfizer shares experiences in transforming a generic drug into a new drug through collaboration, which can be emulated by counterparts.

In summary, case studies can not only be resources that catalog the work of a company, they can also be useful for instruction and in furthering the business of the company.

In this section we describe two case studies by a contract research, development, and manufacturing organization (CRDMO). In the first example, the CRDMO documents how they catered to a biotech company which approached them for manufacturing antibodies. The case study starts with a section ‘Requirement’, which states the aim of the partnership, and highlights the expertise of the CRDMO which brought the client to them; which is biologics and monoclonal antibody manufacturing. The requirement section is immediately followed by the ‘Solution’ section, which mentions the workflow involved, once again focusing on the experimental expertise of the CRDMO in manufacturing the antibodies. The case study is concluded with a brief description of the outcome for the client which involved better efficiency of the production pipeline. The case study ends with a call to action to talk to their experts. In another example, the CRDMO showcases their green chemistry expertise which reduced manufacturing costs and wastage for their client. The case study starts with an overview, followed by the requirement, which was the synthesis of 250kg of an oncology product. This section is followed by a ‘Challenge’ section, which describes the complex chemistry involved and the difficulties faced by the client. In the solution section, the company describes how a cross-functional team was put together to develop a chemical process based on green principles. They executed process development and optimization through a process flow they named as SELECT. They also present a step-by-step comparison of the earlier workflow to the optimised workflow. In the conclusion section, the company underscores the wider adaptability of their solution for other clients as well. Once again, the case study document ends with a CTA.

Overall, Syngene’s case studies are concise short form writings without much insights into the data involved, in contrast to the whitepapers published by the same company. This shows that the company used case studies to provide a quick glimpse into their science and expertise.

Imagine your readers are extremely busy people who want a quick shot of your science and why they should collaborate with you? Most healthcare providers are short of time and yet as a CRO, CDMO or any other biotech or medtech firm, you want them to go through your case studies. This resource by aha media talks about the The Anatomy of a Great B2B Healthcare Case Study that can appeal to healthcare providers and other audience. The article divides a case study into six sections, each of which has a definitive structure. Give this article a read to write concise and compelling case studies for your company.

In this edition, we highlight our work for The Centre for Cellular and Molecular Platforms (C-CAMP), where through two blogs, we summarise the innovations and initiatives around anti-microbial resistance (AMR). In the first blog of the series, we describe the imminent threat from anti-microbial resistance and the efforts of CARB-X. CARB-X is a globally recognized non-profit organization that supports the development of innovative products to combat drug-resistant bacteria. Through the second blog we discuss broad spectrum and narrow spectrum antibiotics and call for their judicious use to tackle the issue of AMR.

Have you read our latest article yet?